Pharmaceutical Contract Development And Manufacturing Organization (CMO) Market Expansion Is Opening New Pathways For Strategic Investment
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Pharmaceutical Contract Development And Manufacturing Organization (CMO) Market Size Forecast: How Large Could The Market Become By 2030?
The market for contract development and manufacturing organizations (CDMOs) in the pharmaceutical sector has experienced significant expansion over the past few years. Projections indicate an increase from $54.73 billion in 2025 to $60.7 billion in 2026, reflecting a compound annual growth rate (CAGR) of 10.9%. This historic growth has been driven by factors such as heightened research and development spending among pharmaceutical firms, a growing incidence of chronic illnesses, surging demand for generic medications, innovations in drug production technologies, and an intensified emphasis on preclinical and clinical studies.
The pharmaceutical contract development and manufacturing organization (CMO) market is projected to experience significant expansion over the coming years, reaching an estimated value of $90.76 billion by 2030, driven by a compound annual growth rate (CAGR) of 10.6%. Several factors are fueling this forecasted growth, such as the increasing uptake of personalized medicine, heightened demand for biologics and intricate therapeutics, the broadening of CDMO capabilities in emerging markets, the incorporation of digital technologies into drug development processes, and a surge in strategic collaborations and mergers within the pharmaceutical industry. Key trends shaping this period include a stronger reliance on outsourcing for drug development and manufacturing, an expansion in the range of services offered by CDMOs, a heightened emphasis on regulatory adherence and quality assurance, the formation of alliances between pharmaceutical companies and CDMOs, and the integration of sophisticated analytical and testing services.
Download A Free Sample Report For Comprehensive Market Insights:
Pharmaceutical Contract Development And Manufacturing Organization (CMO) Market Expansion Drivers: What Is Shaping Future Growth?
A growing wave of patent expirations is anticipated to drive expansion in the pharmaceutical contract development and manufacturing market. Patent expiration marks the conclusion of the legally protected exclusive rights granted to an inventor or patent holder, which allow them to make, sell, or use an invention for a set duration. Contract development and manufacturing services in the pharmaceutical sector facilitate the rapid development and production of generic drugs, enabling them to enter the market once patent protections lapse. For example, as reported by DrugTimes, a Chinese company focused on the pharmaceutical and biotech industry, in February 2024, over 25 products will lose their patent protection by 2037. Based on 2024 sales figures, this could result in a combined revenue decline exceeding $236.4 billion. Consequently, the rising incidence of patent expirations is fueling growth in the pharmaceutical contract development and manufacturing market.
Pharmaceutical Contract Development And Manufacturing Organization (CMO) Market Categorization By Product Type And Application
The pharmaceutical contract development and manufacturing organization (cmo) market covered in this report is segmented –
1) By Type: Contract Manufacturing Services, Contract Research Services
2) By Research Phase: Preclinical, Phase I, Phase II, Phase III, Phase IV
3) By End User: Big Pharmaceutical Companies, Generic Pharmaceutical Companies, Small And Medium-Sized Pharmaceutical Companies
Subsegments:
1) By Contract Manufacturing Services: Active Pharmaceutical Ingredient (API) Manufacturing, Formulation Development, Finished Dosage Form Manufacturing, Packaging Services, Supply Chain Management
2) By Contract Research Services: Preclinical Research Services, Clinical Trial Management, Regulatory Affairs Consulting, Biostatistics And Data Management, Analytical And Testing Services
Pharmaceutical Contract Development And Manufacturing Organization (CMO) Market Strategic Trends: What Is Defining The Next Phase Of Growth?
Major players in the pharmaceutical contract development and manufacturing industry are introducing innovative offerings like the DevPack to strengthen their service portfolios and address the sector’s changing demands. This DevPack is a service designed to be coordinated across multiple collaborators, producing a consistent dataset of development process steps. For example, ASM Research Chemicals, a German business specializing in contract research and manufacturing, unveiled the DevPack in May 2023. This new development package is tailored for the production of active pharmaceutical ingredients (APIs). The DevPack, refined through partnerships with ten key organizations, delivers a standardized dataset for development workflows. It helps streamline API research, development, and scaling efforts. Geared toward CMOs and pharmaceutical companies seeking rapid early-stage manufacturing routes for APIs, this service also facilitates analytical development and is well-suited for quick route implementation.
Pharmaceutical Contract Development And Manufacturing Organization (CMO) Market Company Landscape And Strategic Competition
Major companies operating in the pharmaceutical contract development and manufacturing organization (cmo) market are Lonza Group, Catalent Inc, WuXi AppTec Inc., Recipharm AB, Almac Group, Aenova Group, Baxter International Inc, SGS Life Science Services SA, Jubilant Pharmova Ltd, Dishman Pharmaceuticals, Kemwell Pvt. Ltd., Nipro Corp., CMIC Group, Sawai Pharmaceutical Co. Ltd, IDT Australia Limited, Aurigene Pharmaceutical Services Limited, Vetter Pharma International GMBH, Consort Medical PLC, Siegfried Holding AG, Evonik Industries, NextPharma, Royal DSM N.V, HAUPT Pharma AG, Famar, OTC-PharmNEUCA, Farmacol, Polska Grupa Farmaceutyczna, Polpharma, TZMO, Eurofarma Laboratórios S.A., Ache Laboratórios Farmacêuticos S.A., Blanver Farmoquímica e Farmacêutica S.A., Prati-Donaduzzi, União Química Farmacêutica Nacional S.A, Laboratorios Richmond S.A.C.I.F., Bago S.A., Elea Laboratories S.A.C.I. y F., Gador S.A., LIFEPharma, Neopharm, Gulf Pharmaceutical Industries JULPHA, NewBridge Pharmaceuticals Limited, Aspen Pharmacare Holdings Limited, Adcock Ingram Holdings Limited, Pharma-Q (Pty) Ltd, Vital Health Foods, EIPICO (Egyptian International Pharmaceutical Industries Company), Pharco Pharmaceuticals
Access The Complete Pharmaceutical Contract Development And Manufacturing Organization (CMO) Market Report:
Pharmaceutical Contract Development And Manufacturing Organization (CMO) Market Regional Outlook: Where Are The Largest Opportunities Located?
North America was the largest region in the global pharmaceutical contract development and manufacturing market in 2025. The Middle East is expected to be the fastest-growing region in the global pharmaceutical contract development and manufacturing market during the forecast period. The regions covered in the pharmaceutical contract development and manufacturing organization (cmo) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
